Drugs / ISIS-FXIRx
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01713361 | Oct 2012 → May 2014 | venous thromboembolism | Ionis Pharmaceuticals, Inc. | Completed | Met primary |
Press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2012-10-29 | Ionis Pharmaceuticals | Isis Initiates Phase 2 Study Of ISIS-FXIRX In Patients Undergoing Knee Replacement Surgery ionis.com ↗ |
| 2011-12-12 | Ionis Pharmaceuticals | Isis Reports Positive Phase 1 Data Demonstrating ISIS-FXIRx Reduces Factor XI Activity Without Bleeding ionis.com ↗ |
| 2011-02-02 | Ionis Pharmaceuticals | Isis Initiates Phase 1 Clinical Trial of ISIS-FXIRx to Treat Clotting Disorders ionis.com ↗ |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ISIS-FXIRx | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01713361 ↗ |
| Known as | FXI-ASO | “FXI-ASO (ISIS 416858) is a second-generation antisense oligonucleotide that specifically reduces factor XI levels.” PMID 25482425 ↗ Dec 2014 |
| Known as | ISIS 416858 | “FXI-ASO (ISIS 416858) is a second-generation antisense oligonucleotide that specifically reduces factor XI levels.” PMID 25482425 ↗ Dec 2014 |
| Action | Inhibit | “specifically reduces factor XI levels” PMID 25482425 ↗ Dec 2014 |
| Modality | Antisense oligonucleotide | “FXI-ASO (ISIS 416858) is a second-generation antisense oligonucleotide that specifically reduces factor XI levels.” PMID 25482425 ↗ Dec 2014 |
| Route | Subcutaneous | “subcutaneously administered” NCT01713361 ↗ |
| Target | F11 | “specifically reduces factor XI levels” PMID 25482425 ↗ Dec 2014 |